Cancer Research Technology Limited

Gregoire A Pave

Robert L Hudkins

Bruce D Dorsey

Allison L Zulli

Gregory R Ott

Craig A Zificsak

Eugen F Mesaros

Benjamin J Dugan

Christelle N Soudy

Emma L Morris

Katherine M Fowler

Nathaniel J T Monck

Ikeoluwa Olowoye

Henry Joseph Breslin

Ming Tao

Jonathan R A Roffey

Jonathan R Roffey

Nathaniel Jt Monck

Henry J Breslin

Jonathan RA Roffey

The present application provides a compound of formula (I) and/or a salt thereof, wherein R, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

Azaquinazoline inhibitors of atypical protein kinase C

The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C ('aPKC') inhibitory activity, and may be used to treat proliferative disorders.

Azaquinazoline inhibitors of Atypical protein Kinase C

The present application provides a compound of formula (I) or a salt thereof, wherein R, R, R, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

Growing community of inventors

London, United Kingdom

Gregoire A Pave